Cargando…

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease

BACKGROUND: Vedolizumab, an α4β7 integrin antagonist, is an effective therapy for Crohn’s disease (CD). Biomarkers are needed to guide therapy and predict outcomes. This study evaluated biomarker concentrations and outcomes in patients with CD undergoing vedolizumab treatment. METHODS: Sera at weeks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holmer, Ariela K., Battat, Robert, Dulai, Parambir S., Vande Casteele, Niels, Nguyen, Nghia, Jain, Anjali, Miralles, Ara, Neill, Jennifer, Le, Helen, Singh, Siddharth, Rivera-Nieves, Jesus, Sandborn, William J., Boland, Brigid S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675888/ https://www.ncbi.nlm.nih.gov/pubmed/33240396 http://dx.doi.org/10.1177/1756284820971214

Ejemplares similares

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease
por: Arulanandan, Ahilan, et al.
Publicado: (2016)

Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease
por: Dulai, Parambir S, et al.
Publicado: (2022)

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
por: Faleck, David M., et al.
Publicado: (2019)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease
por: Dulai, Parambir S., et al.
Publicado: (2019)

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
por: Sandborn, William J, et al.
Publicado: (2019)

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes
por: Dulai, Parambir S, et al.
Publicado: (2020)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
por: Boland, Brigid S., et al.
Publicado: (2022)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
por: Koliani-Pace, Jenna L, et al.
Publicado: (2019)

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
por: Vande Casteele, N., et al.
Publicado: (2017)

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
por: Vermeire, Séverine, et al.
Publicado: (2021)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice
por: Vande Casteele, Niels, et al.
Publicado: (2020)

Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring
por: Hemperly, Amy, et al.
Publicado: (2021)

Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study
por: Vande Casteele, Niels, et al.
Publicado: (2020)

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies
por: Dulai, Parambir S., et al.
Publicado: (2019)

The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
por: Kapila, Nikhil, et al.
Publicado: (2018)

Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn’s Disease
por: Verdon, Christine, et al.
Publicado: (2020)

Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies
por: Boland, Brigid S., et al.
Publicado: (2022)

Location-specific signatures of Crohn’s disease at a multi-omics scale
por: Gonzalez, Carlos G., et al.
Publicado: (2022)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab
por: Yeh, Jennifer E., et al.
Publicado: (2017)

Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn’s Disease
por: Busutti, Marco, et al.
Publicado: (2023)

Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity
por: Fang, Xin, et al.
Publicado: (2020)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient
por: Groudan, Kevin, et al.
Publicado: (2021)

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
por: Zhou, Ting, et al.
Publicado: (2021)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
por: Ayoub, Fares, et al.
Publicado: (2022)

Orbital Myositis in a Patient With Ileal Crohn's Disease in Remission on Vedolizumab
por: Sandhu, Sunny, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f8s2e78lb293nd5oak0b5d27qq